- Home
- DBRG vs CPRX Comparison
DBRG vs CPRX Comparison
Compare DBRG & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | CPRX |
|---|---|---|
| Founded | 1991 | 2002 |
| Country | United States | United States |
| Employees | 311 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | DBRG | CPRX |
|---|---|---|
| Price | $15.70 | $31.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $16.00 | ★ $35.00 |
| AVG Volume (30 Days) | 2.7M | ★ 3.2M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $373.39 | $9.20 |
| Revenue Next Year | $8.23 | $10.51 |
| P/E Ratio | $252.25 | ★ $62.51 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $8.94 | $19.05 |
| 52 Week High | $15.72 | $32.56 |
Technical Indicators
Market Signals| Indicator | DBRG | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 71.54 | 72.98 |
| Support Level | $15.33 | $22.24 |
| Resistance Level | N/A | $31.29 |
| Average True Range (ATR) | 0.03 | 0.31 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 91.18 | 95.59 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.